Cargando…

Inhibition of LDH-A by Oxamate Enhances the Efficacy of Anti-PD-1 Treatment in an NSCLC Humanized Mouse Model

Immunotherapy is a curable treatment for certain cancers, but it is still only effective in a small subset of patients, partly because of the lack of sufficient immune cells in the tumor. It is reported that targeted lactate dehydrogenase (LDH) to reduce lactic acid production can promote the infilt...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qiao, Tianyun, Xiong, Yanlu, Feng, Yangbo, Guo, Wenwen, Zhou, Yongsheng, Zhao, Jinbo, Jiang, Tao, Shi, Changhong, Han, Yong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8042335/ https://www.ncbi.nlm.nih.gov/pubmed/33859941 http://dx.doi.org/10.3389/fonc.2021.632364

Ejemplares similares

Combined pembrolizumab and bevacizumab therapy effectively inhibits non-small-cell lung cancer growth and prevents postoperative recurrence and metastasis in humanized mouse model
por: Qiao, Tianyun, et al.
Publicado: (2022)

Correction to: Combined pembrolizumab and bevacizumab therapy effectively inhibits non-small-cell lung cancer growth and prevents postoperative recurrence and metastasis in humanized mouse model
por: Qiao, Tianyun, et al.
Publicado: (2022)

Oxamate, but Not Selective Targeting of LDH-A, Inhibits Medulloblastoma Cell Glycolysis, Growth and Motility
por: Valvona, Cara J., et al.
Publicado: (2018)

Gene expression-based clinical predictions in lung adenocarcinoma
por: Xiong, Yanlu, et al.
Publicado: (2020)

Different effects of LDH-A inhibition by oxamate in non-small cell lung cancer cells
por: Yang, Yang, et al.
Publicado: (2014)

Strategies for the Construction of Mouse Models With Humanized Immune System and Evaluation of Tumor Immune Checkpoint Inhibitor Therapy
por: Guo, Wenwen, et al.
Publicado: (2021)

Synergistic Anti-Cancer Effect of Phenformin and Oxamate
por: Miskimins, W. Keith, et al.
Publicado: (2014)

TFAP2A potentiates lung adenocarcinoma metastasis by a novel miR-16 family/TFAP2A/PSG9/TGF-β signaling pathway
por: Xiong, Yanlu, et al.
Publicado: (2021)

Crystal structure of oxamyl
por: Kwon, Eunjin, et al.
Publicado: (2016)

A gene-based survival score for lung adenocarcinoma by multiple transcriptional datasets analysis
por: Xiong, Yanlu, et al.
Publicado: (2020)

Combination of Metformin, Sodium Oxamate and Doxorubicin Induces Apoptosis and Autophagy in Colorectal Cancer Cells via Downregulation HIF-1α
por: Coronel-Hernández, Jossimar, et al.
Publicado: (2021)

Radiation Plus Anti-PD-1 Therapy for NSCLC Brain Metastases: A Retrospective Study
por: Liao, Guixiang, et al.
Publicado: (2021)

Lactate dehydrogenase A: A key player in carcinogenesis and potential target in cancer therapy
por: Feng, Yangbo, et al.
Publicado: (2018)

Patients With Short PFS to EGFR-TKIs Predicted Better Response to Subsequent Anti-PD-1/PD-L1 Based Immunotherapy in EGFR Common Mutation NSCLC
por: Liu, Sangtian, et al.
Publicado: (2021)

Research Progress of Anti-PD-1/PD-L1 Immunotherapy Related Mechanisms and Predictive Biomarkers in NSCLC
por: Bie, Fenglong, et al.
Publicado: (2022)

Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression
por: Masuda, Ken, et al.
Publicado: (2020)

Predictive effect of molecular and clinical characteristics for the OS and PFS efficacy of anti-PD-1/PD-L1 immunotherapy in patients with NSCLC: a meta-analysis and systematic review
por: An, Rui, et al.
Publicado: (2021)

PD-1(+) IFN-γ(+) subset of CD8(+) T cell in circulation predicts response to anti–PD-1 therapy in NSCLC
por: Chen, Wenxiu, et al.
Publicado: (2023)

Oxamate Attenuates Glycolysis and ER Stress in Silicotic Mice
por: Mao, Na, et al.
Publicado: (2022)

Ammonium N-(pyridin-2-ylmethyl)oxamate (AmPicOxam): A Novel Precursor of Calcium Oxalate Coating for Carbonate Stone Substrates
por: Pintus, Anna, et al.
Publicado: (2023)

Primary tumour category, site of metastasis, and baseline serum S100B and LDH are independent prognostic factors for survival in metastatic melanoma patients treated with anti-PD-1
por: Janka, Eszter Anna, et al.
Publicado: (2023)

Comparison of Metabolic and Morphological Response Criteria for Early Prediction of Response and Survival in NSCLC Patients Treated With Anti-PD-1/PD-L1
por: Castello, Angelo, et al.
Publicado: (2020)

2-Fluoroanilinium N-(2-fluorophenyl)oxamate
por: Büyükgüngör, Orhan, et al.
Publicado: (2008)

Oxamate enhances the efficacy of CAR-T therapy against glioblastoma via suppressing ectonucleotidases and CCR8 lactylation
por: Sun, Ting, et al.
Publicado: (2023)

The Efficacy and Safety of Regorafenib in Combination With Anti-PD-1 Antibody in Refractory Microsatellite Stable Metastatic Colorectal Cancer: A Retrospective Study
por: Li, Jisheng, et al.
Publicado: (2020)

High Pretreatment LDH Predicts Poor Prognosis in Hypopharyngeal Cancer
por: Wu, Jialing, et al.
Publicado: (2021)

A Combined-Radiomics Approach of CT Images to Predict Response to Anti-PD-1 Immunotherapy in NSCLC: A Retrospective Multicenter Study
por: Wu, Minghao, et al.
Publicado: (2022)

Oncolytic Adenoviral Vector-Mediated Expression of an Anti-PD-L1-scFv Improves Anti-Tumoral Efficacy in a Melanoma Mouse Model
por: Vitale, Maria, et al.
Publicado: (2022)

Immune-Related Adverse Events Associated With Outcomes in Patients With NSCLC Treated With Anti-PD-1 Inhibitors: A Systematic Review and Meta-Analysis
por: Zhao, Zhe, et al.
Publicado: (2021)

PD-L1 Test-Based Strategy With Nivolumab as the Second-Line Treatment in Advanced NSCLC： A Cost-Effectiveness Analysis in China
por: Liu, Qiao, et al.
Publicado: (2021)

Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
por: Seidel, Judith A., et al.
Publicado: (2018)

HDAC10 Is Positively Associated With PD-L1 Expression and Poor Prognosis in Patients With NSCLC
por: Liu, Xiaomei, et al.
Publicado: (2020)

Role of sex and sex hormones in PD-L1 expression in NSCLC: clinical and therapeutic implications
por: Rodriguez-Lara, Vianey, et al.
Publicado: (2023)

Predictive value of LDH kinetics in bevacizumab treatment and survival of patients with advanced NSCLC
por: Li, Butuo, et al.
Publicado: (2018)

The Multi-Modal Effect of the Anti-fibrotic Drug Pirfenidone on NSCLC
por: Marwitz, Sebastian, et al.
Publicado: (2020)

Pembrolizumab Alone or Combined With Chemotherapy in Advanced NSCLC With PD-L1 ≥50%: Results of a Retrospective Study
por: Chen, Ya, et al.
Publicado: (2021)

Cost-Effectiveness of Ipilimumab Plus Anti-PD-1 Therapy Versus Ipilimumab Alone in Patients With Metastatic Melanoma Resistant to Anti-PD-(L)1 Monotherapy
por: Peng, Ye, et al.
Publicado: (2021)

Comparison of Efficacy and Safety Between Immunotherapy and Docetaxel Monotherapy in NSCLC Patients
por: Yang, Wenchao, et al.
Publicado: (2022)

Blockade of Lactate Dehydrogenase-A (LDH-A) Improves Efficacy of Anti-Programmed Cell Death-1 (PD-1) Therapy in Melanoma
por: Daneshmandi, Saeed, et al.
Publicado: (2019)

Restored CD8(+)PD-1(+) T Cells Facilitate the Response to Anti-PD-1 for Patients With Pancreatic Ductal Adenocarcinoma
por: Zhu, Qian, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_319a88b9mobt96a2ttf725p2ji